



Noninvasive Cancer Diagnostics:

*Technologies and Global
Markets*

August 2017

Paul Taylor

Report Code: HLC197A

Table of Contents

Chapter 1: Introduction	1
Study Goals and Objectives.....	2
Scope of Report.....	2
Methodology and Information Sources	3
Primary Data and Information Gathering	3
Secondary Data and Information Gathering	4
Market Share Analysis and Market Forecast Prediction	4
Geographic Breakdown.....	5
Analyst's Credentials.....	9
Related BCC Research Reports.....	9
Chapter 2: Summary and Highlights	11
Summary of Key Findings.....	11
Diagnostic Imaging Segment	13
Advanced Diagnostics Segment	13
Conventional Segment	14
Chapter 3: Market and Technology Review: Diagnostic Imaging	16
Real-time In Vivo Cancer Diagnosis using Raman Spectroscopy	16
In-Vivo Fluorescence Imaging in Personalized Cancer Diagnostics	18
Direct Imaging	18
Indirect Fluorescence Imaging	19
Magnetic Resonance Imaging (MRI) Scans	19
Development to the RF Subsystem	22
Positron Emission Tomography (PET) Scan.....	26
Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)	29
Mammography	31
Digital Mammography Systems	32
Breast Tomosynthesis Systems	35
Ultrasound	36
Barium Swallow or Enema	41
Bone Scans (MRI, CT and PET)	42
Market Estimate	42
Chapter 4: Market and Technology Review: Advanced Noninvasive Cancer Diagnostic Assays and Technologies	44
Introduction to Circulating Nucleic Acids (CNAs).....	46
Circulating Nucleic Acids as a Diagnostic Tool	49
Circulating DNA as a Biomarker of Cancer	50
Use of Circulating DNA for Prenatal Diagnosis (Conventional).....	50
Use of Circulating DNA for Prenatal Diagnosis (Noninvasive).....	51
Circulating RNA as a Biomarker of Cancer	51
Methods Used for the Detection of Circulating Nucleic Acids.....	55
Liquid Biopsy	56
Janssen Diagnostics	58
Roche Molecular Systems Inc.....	59
Genomic Health.....	59

Foundation Medicine	60
Veracyte	60
Trovogene Inc.	60
Myriad Genetics	61
OncoCyte Corp.	61
Illumina	61
NeoGenomics Laboratories	62
Biocept Inc.	62
Vermillion Inc.	63
Sysmex Inostics, a subsidiary of Sysmex Corp.	63
Guardant Health	63
Product Development and New Initiatives in Liquid Biopsy	63
Molecular Cytogenetic/Gene Expression Studies	65
Amplify and Detect Diminished Amounts of RNA Consistently	68
Analyze Hundreds of Genes	69
Proteomics and New Protein Markers	69
Inside the ProteinChip System	70
Proteome Pattern Recognition	71
Next-Generation Sequencing (NGS) Studies	72
Illumina Solexa System	73
Roche 454 Sequencing	73
Thermo Fisher Scientific Ion Personal Genome Machine (PGM)	74
Thermo Fisher Scientific SOLiD (Sequencing by Oligonucleotide Ligation and Detection)	74
Oxford Nanopore Technologies	75
The Third-Generation Sequencer	75
Clinical Acceptance of a New Diagnostic Assay	76
Saliva-Based Oral Cancer Diagnostics	78
Advanced Tissue Staining (Immunohistochemistry (IHC) and in situ Hybridization (ISH))	79
Optical Biopsy	80
Market Estimate	81

Chapter 5: Market and Technology Review: Conventional Noninvasive Cancer

Diagnostic Assays and Tests	83
Pap Test and HPV Testing	84
Tumor Biomarker Testing	86
MammaPrint Specifications	92
Genomic Health's Oncotype DX Breast Cancer Test	93
The Prosigna Breast Cancer Prognostic Gene Signature Assay (formerly called the PAM50 test)	94
Sales and Marketing Strategies for Cancer Tests	95
Fecal Occult Blood Tests (FOBT)	97
Digital Rectal Exam (DRE)	100
Multigated Acquisition (MUGA) Scans	100
Market Estimate	101

Chapter 6: Incidence, Prevalence and Mortality Statistics for Cancer: A Global

Summary	103
Cancer: The Disease	103
Cancer: A Statistical Analysis of the Disease Incidence and Prevalence	104
Incidence and Prevalence Rates for Major Cancer Types	104
Regional Patterns of Cancer	113
Europe	113

North America	113
Asia-Pacific.....	115
Latin and Central America	116
Middle East/Africa.....	116
The Global Cancer Burden and Worldwide Cancer Risk Factors	117
Tobacco Use and Statistics	117
Alcohol Abuse and Cancer Statistics	118
Obesity and Cancer Statistics	118
Infectious Diseases and Cancer	118
Inherited Genes/Diseases and Cancer	119
Sun, U.V. and Cancer	120
Hormones and Cancer	120
Chapter 7: Noninvasive Cancer Diagnostics Market by Cancer Type.....	122
Global Noninvasive Cancer Diagnostics Market, by Cancer Type.....	122
Global Market Drivers	127
Global Market Restraints	131
Regional Noninvasive Cancer Diagnostics Market Assessment: North America	133
Selected Market Drivers: North America	133
Selected Market Restraints: North America	136
Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type.....	138
Regional Noninvasive Cancer Diagnostics Market Assessment: Europe	140
Selected Market Drivers: Europe	141
Selected Market Restraint: Europe	143
Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type.....	144
Regional Noninvasive Cancer Diagnostics Market Assessment: Asia-Pacific	152
Selected Market Drivers: Asia-Pacific.....	153
Selected Market Restraints: Asia-Pacific.....	157
Regional Noninvasive Cancer Diagnostics Market Assessment: Central and Latin America	162
Selected Market Drivers: Central and Latin America	163
Selected Market Restraints: Central and Latin America	166
Regional Noninvasive Cancer Diagnostics Market Assessment: Middle East/Africa.....	171
Selected Market Drivers: Middle East/Africa.....	174
Selected Market Restraints: Middle East/Africa	175
Chapter 8: Market Analysis by Technology, End User and Market Share	179
Global Noninvasive Cancer Diagnostics Market, by Technology.....	179
Regional Noninvasive Cancer Diagnostics Market, by Technology: North America	183
Regional Noninvasive Cancer Diagnostics Market, by Technology: Europe	186
Regional Noninvasive Cancer Diagnostics Market, by Technology: Asia-Pacific.....	189
Regional Noninvasive Cancer Diagnostics Market, by Technology: Central and Latin America	191
Regional Noninvasive Cancer Diagnostics Market, by Technology: Middle East/Africa	194
Global Noninvasive Cancer Diagnostics Market, by End-User.....	196
General Clinical Reference Laboratories	199
Market Share Analysis by Technology: Noninvasive Cancer Diagnostics Market.....	200
Chapter 9: Technological Advances, Trends and Opportunities	211
Key Technological Developments and Advances, Market Trends and Opportunities.....	211
Developments and Advances, Trends and Opportunities in Diagnostic Imaging	211
Developments and Advances, Trends and Opportunities in Advanced Noninvasive Approaches	214
Developments and Advances, Trends and Opportunities in Screening Assays	217

Opportunities for IVD/MIA Companies	220
Chapter 10: Regulatory and Legislative Requirements.....	223
United States.....	223
How are IVDs Classified?	223
FDA Regulations Relating to Companion Diagnostics	226
Laboratory Developed Tests (LDTs).....	227
Centers for Medicare & Medicaid Services (CMS)	228
The 2010 Affordable Care Act	229
Private Insurance.....	229
Europe.....	231
(General) Medical Device Directive, MDD (93/42/EEC)	232
Active Implantable Medical Device Directive, AIMDD (90/383/EEC.....	233
In Vitro Diagnostic Medical Device Directive, IVDMDD (98/79/EC).....	234
Proposal for Changes to the Medical Device Directive, MDD (93/42/EEC)	234
Japan	236
Marketing Authorization System	237
China	239
Overview of the Healthcare System.....	239
Healthcare Reforms.....	241
Healthcare Institutions	241
India	245
Overview of the Healthcare System.....	245
Hospital Resources	248
Population Statistics.....	249
South Korea.....	250
Brazil.....	251
Background.....	251
Regulatory and Legislative Requirements.....	253
Market Entry and Reimbursement of Medical Devices: Brazil.....	254
Argentina.....	255
Background.....	255
Government-funded Public Health Sector	256
Social Health Insurance Sector	256
Private Sector	257
Regulatory and Legislative Requirements.....	257
Mexico.....	258
Legislation and Regulations Governing Medical Devices in Mexico	259
Health Insurance Structure in Mexico.....	260
Chapter 11: Patent Review of Key Technologies	262
Microarray Patents	263
LOAC Patents.....	268
Clinical Next-Generation Sequencing (NGS) Patents.....	270
Clinical NGS Patents Summary	270
Clinical NGS Patents by Indication.....	272
Chapter 12: Company Profiles	275
Appendix A: Company Addresses and Contact Details	335
Appendix B: Government Regulatory Agencies and Professional Organizations	349

Appendix C: Commonly Used Acronym Associated with Noninvasive Cancer

Diagnostics.....	354
About BCC Research.....	365
About BCC Research.....	366
BCC Membership	366
BCC Custom Research	366

List of Tables

Summary Table Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions)	12
Table 1 Diagnostic Imaging Segment	13
Table 2 Advanced Segment.....	14
Table 3 Conventional Segment	14
Table 4 Noninvasive Cancer Diagnostics Market Segmentation	16
Table 5 Breast MRI Systems Currently Available	20
Table 6 Wide Bore MRI Systems Currently Available	21
Table 7 PET/CT Systems Currently Available	27
Table 8 PET/MR Systems Currently Available.....	31
Table 9 Key trends in (Digital Mammography Systems)	33
Table 10 Digital Mammography Systems Currently Available.....	33
Table 11 Breast Tomosynthesis Systems Currently Available	36
Table 12 Benefits of Medical Ultrasound Imaging.....	37
Table 13 Regulatory Approval for High-intensity Focused Ultrasound (HIFU) by Region	38
Table 14 Ultrasound Systems Currently Available	39
Table 15 Noninvasive Cancer Diagnostics Market Segmentation	45
Table 16 Major Developments in Understanding Nucleic Acids and their Cellular Roles	47
Table 17 Circulating Tumor-associated miRNAs as Potential Cancer Biomarkers.....	52
Table 18 Key Elements for Business Competition in Gene Expression Profiling for Cancer	65
Table 19 DNA Microarray Diagnostic Test Adoption Rate	76
Table 20 Characteristics of in situ Hybridization Methods	80
Table 21 Key Advantages of Optical Biopsy Systems.....	81
Table 22 Noninvasive Cancer Diagnostics Market Segmentation	84
Table 23 Key Drivers to Adoption of Biomarkers in Clinical Use	88
Table 24 Key Barriers to Adoption of Biomarkers in Clinical Use	88
Table 25 Tumor Biomarkers Currently in Common Clinical Use.....	89
Table 26 MammaPrint: Key Features.....	93
Table 27 Strategies for Marketing Cancer Diagnostic Products	96
Table 28 Advantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT))	98
Table 29 Disadvantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT))	98
Table 30 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence, 2012	105
Table 31 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (In Men and Women Combined) by Cancer Type, 2012	106
Table 32 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (Men) by Cancer Type, 2012.....	109
Table 33 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (Women) by Cancer Type, 2012.....	111
Table 34 Estimated Number of New Cancer Cases by Sex: United States, 2017 (%)	114
Table 35 Estimated Number of Deaths from Cancer by Sex: United States, 2017	115
Table 36 Global Noninvasive Cancer Diagnostics Market, Through 2022 (\$ Millions)	122
Table 37 Global Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions). 123	
Table 38 Global Noninvasive Cancer Diagnostics Market and Market Share, by Cancer Type, 2017 (%)	124
Table 39 Global Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%).....	126
Table 40 North American Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	134

Table 41 Sample Listing of Payers that Published Positive Coverage Policies for KRAS Testing	135
Table 42 United States Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	138
Table 43 Canada Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	140
Table 44 European Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	141
Table 45 Europe: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)	142
Table 46 France Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	145
Table 47 Germany Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	146
Table 48 Italy Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	147
Table 49 Spain Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions) ...	148
Table 50 U.K. Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	149
Table 51 Benelux Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	150
Table 52 Scandinavia Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	151
Table 53 Rest of Europe Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	152
Table 54 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	153
Table 55 Asia-Pacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%).....	154
Table 56 China: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)..	160
Table 57 India: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 (\$ Millions) ...	160
Table 58 Japan: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 (\$ Millions) ..	161
Table 59 South Korea: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	161
Table 60 Rest of Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	162
Table 61 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	163
Table 62 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)	164
Table 63 Argentina: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	168
Table 64 Brazil: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)..	169
Table 65 Chile: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)...	169
Table 66 Mexico: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)...	170
Table 67 Rest of Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions).....	171
Table 68 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	172
Table 69 Middle East/Africa: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)	173
Table 70 Middle East: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions)	176
Table 71 Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 (\$ Millions) .	177
Table 72 Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions)...	180
Table 73 Global Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 (\$ Millions)	181
Table 74 Global Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 (\$ Millions).....	182

Table 75 Global Noninvasive Cancer Diagnostics Market, by Conventional Noninvasive Cancer Screening and Diagnostic Assays and Tests Technology, Through 2022 (\$ Millions).....	182
Table 76 North America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions)	183
Table 77 North American: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 (\$ Millions).....	184
Table 78 North American: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 (\$ Millions).....	185
Table 79 North American: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 (\$ Millions).....	185
Table 80 Europe: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions).186	
Table 81 Europe: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 (\$ Millions)	187
Table 82 Europe: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 (\$ Millions).....	188
Table 83 Europe: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 (\$ Millions)	188
Table 84 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions)	189
Table 85 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 (\$ Millions).....	190
Table 86 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 (\$ Millions).....	190
Table 87 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 (\$ Millions)	191
Table 88 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions)	192
Table 89 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 (\$ Millions).....	192
Table 90 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 (\$ Millions).....	193
Table 91 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 (\$ Millions)	193
Table 92 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 (\$ Millions)	194
Table 93 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 (\$ Millions).....	195
Table 94 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 (\$ Millions).....	195
Table 95 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 (\$ Millions).....	196
Table 96 Global Noninvasive Cancer Diagnostics Market, by End-User, Through 2022 (\$ Millions).....	197
Table 97 Global Market Share for Diagnostic Imaging, Noninvasive Cancer Diagnostics, by Company, 2017 (%)	201
Table 98 Global Market Share for Advanced Noninvasive Approaches, Noninvasive Cancer Diagnostics, by Company, 2017 (%)	202
Table 99 Global Market Share for Molecular Signature-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%).....	203
Table 100 Global Market Share for DNA Microarray-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)	204

Table 101 Global Market Share for Cytogenetic/Gene Expression-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)	205
Table 102 Global Market Share for Circulating Nucleic Acid (CNA)-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)	206
Table 103 Global Market Share for Screening Assays, Noninvasive Cancer Diagnostics, by Company, 2017 (%)	207
Table 104 Global Market Share for Fecal Occult Blood Test (FOBT)-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)	208
Table 105 Global Market Share for Tumor Biomarker Test-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)	209
Table 106 Principal Factors Influencing the Growth and Development of Noninvasive Cancer Diagnostics, 2017	212
Table 107 Uses of Tumor Biomarkers in Drug Development.....	219
Table 108 Utility of Biomarkers as Companion Diagnostics to Drug Development	220
Table 109 Overview of Pharmaceutical Affair Law (PAL) and Japanese Medical Device Nomenclature (JMDN) Codes and Related Codes according to the EU MDD.....	237
Table 110 Number of Healthcare Institutions According to Ownership in China, 2010.....	242
Table 111 Total Number of Hospitals by Ranking in China, 2010	243
Table 112 Overview of Healthcare in India	246
Table 113 DNA Microarray Patents by Region, 2002-2012	263
Table 114 Microarray-Related Proteomics Patents by Region, 2002 – 2012	264
Table 115 Microarray-Related Patents by Application and Title, 2017	264
Table 116 Patent Application and Title: Noninvasive Cancer Diagnostics, 2001 – Present.....	266
Table 117 LOAC-Related Proteomics Patents by Region, 2002 – 2012	269
Table 118 LOAC-Related Patents by Application and Title, 2013 – 2015	269
Table 119 Clinical Next Generation Sequencing Patents, 2002–2012.....	270
Table 120 Clinical NGS-Related Patents by Application and Title, 2013 – 2015.....	271
Table 121 Clinical NGS Patents by Indication, 2002–2012	272
Table 122 Abbott Laboratories: Company Financials, Through 2016 (\$ Millions)	278
Table 123 Bayer AG: Company Financials, Through 2016 (\$ Millions)	284
Table 124 bioMerieux S.A. Sales by Application, Through 2016 (\$ Millions)	289
Table 125 Exact Sciences Corp.: Company Financials, Through 2016 (\$ Millions/%)	295
Table 126 Hologic Inc.: Company Financials, 2015-2016 (\$ Millions).....	302
Table 127 Illumina, Inc: Company Financials, 2014-2016 (\$ Millions).....	305
Table 128 Myriad Genetics Inc. Financials, 2014 - 2016 (\$ Millions).....	309
Table 129 Philips Healthcare Financials, Through 2016 (\$ Millions)	313
Table 130 Philips Group Financials by Segment, 2016 (\$ Millions)	314
Table 131 Qiagen N.V. Financials, Through 2016 (\$ Millions)	316
Table 132 Qiagen N.V. Financials by Region, Through 2016 (\$ Millions)	316
Table 133 Quest Diagnostics Financials, Through 2016 (\$ Millions).....	320
Table 134 Roche Group Financials, Through 2016 (\$ Millions)	322
Table 135 Diagnostics Division Financials, 2015 and 2016 (\$ Millions)	322
Table 136 Thermo Fisher Scientific Inc. Financials, Through 2016 (\$ Millions)	330
Table 137 Company Addresses and Contact Details.....	335
Table 138 Government Regulatory Agencies and Professional Organizations Associated with Noninvasive Cancer Diagnostics	349
Table 139 Commonly Used Acronym Associated with Noninvasive Cancer Diagnostics	354

List of Figures

Summary Figure Global Noninvasive Cancer Diagnostics Market, by Technology, 2016-2022 (\$ Millions)	12
Figure 1 Top Molecular CNA Characterization Techniques (%)	57
Figure 2 Market Growth and Evolution of MDx Cancer Biomarkers	95
Figure 3 Estimated Global Cancer Incidence Proportions by Major Sites, In Men and Women Combined, 2012 (%)	108
Figure 4 Estimated World Cancer Incidence Proportions by Major Sites, In Men, 2012 (%)	110
Figure 5 Estimated World Cancer Incidence Proportions by Major Sites, In Women, 2012 (%)	112
Figure 6 Global Market Share for Noninvasive Cancer Diagnostics, by Cancer Type, 2017 (%)	125
Figure 7 Global Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)	126
Figure 8 Average Number of New Cases per Year and Age-Specific Incidence Rates for all Cancers in the U.K., 2012–2014	129
Figure 9 Europe: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)	142
Figure 10 Asia-Pacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)	154
Figure 11 Central and Latin America: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)	165
Figure 12 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)	173
Figure 13 Global Noninvasive Cancer Diagnostics Market, by Technology Type, 2016-2022 (\$ Millions)	180
Figure 14 Global Noninvasive Cancer Diagnostics Market, by End-User, 2016-2022 (\$ Millions)	198
Figure 15 Tumor Biomarker Developments and Market Applications (%)	218
Figure 16 Private Health Insurance Coverage among Persons Under 65 in United States, 2007–2011 (Millions/Percent)	231
Figure 17 The Chinese Healthcare System	240



About BCC Research

About BCC Research

With our unparalleled 45-year history, BCC Research provides comprehensive analysis of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

BCC Membership

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price towards a full membership. Call 866/285-7215 or email info@bccresearch.com to request a demo.

BCC Custom Research

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analysis and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: custom@bccresearch.com or 781-205-2429.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 1-62296-536-1
August 2017